In 2025, U.S. federal regulatory activity hits historic lows under Executive Order 14,192, driving deregulation with a one-in, ten-out rule that reduces net regulatory costs. However, broader federal interventions offset some gains.
ACA marketplace premiums are set to increase by 75% after pandemic-era subsidies expire, risking higher uninsured rates and market instability.
Analysis of federal drug price negotiations under the Inflation Reduction Act, examining perverse incentives in Medicare and private insurance, and exploring Medicare Advantage reforms to improve market efficiency and patient coverage.
The Trump administration plans to reintroduce a 'most favored nation' drug pricing model for Medicare, aiming to align U.S. drug prices with lower international rates. This strategy faces industry opposition but could complement existing Medicare drug price negotiations to reduce costs.
The 2025 NCOIL Spring Meeting in Charleston advances key insurance reforms, including prior authorization, AI in insurance, and prescription drug affordability, with record participation from legislators and regulators.
